Microchip-based device can detect rare tumor cells in bloodstream

404132862 — Thu, 20 Dec 2007 09:37:41 -0500

A team of investigators from the Massachusetts General Hospital (MGH) BioMicroElectroMechanical Systems (BioMEMS) Resource Center and the MGH Cancer Center has developed a microchip-based device that can isolate, enumerate and analyze circulating tumor cells (CTCs) from a blood sample.

Prostate treatment has risks

Thu, 12 Jul 2007 11:53:41 -0400

A treatment mainstay for prostate cancer puts men at increased risk for diabetes and cardiovascular disease, according to a large observational study published in the Sept. 20 Journal of Clinical Oncology.

"Men with prostate cancer have high five-year survival rates, but they also have higher rates of noncancer mortality than healthy men," says study author Nancy Keating, assistant professor of health care policy and of medicine at Harvard Medical School (HMS). "This study shows that a common hormonal treatment for prostate cancer may put men at significant risk for other serious diseases. Patients and physicians need to be aware of the elevated risk as they make treatment decisions."

Prostate cancer treatment increases risk of diabetes, heart disease

70652986 — Mon, 26 Mar 2007 06:28:11 -0400

A treatment mainstay for prostate cancer puts men at increased risk for diabetes and cardiovascular disease, according to a large observational study published in the Sept. 20, 2006, Journal of Clinical Oncology.

"Men with prostate cancer have high five-year survival rates, but they also have higher rates of non-cancer mortality than healthy men," says study author Nancy Keating, MD, MPH, assistant professor of health care policy and of medicine at Harvard Medical School. "This study shows that a common hormonal treatment for prostate cancer may put men at significant risk for other serious diseases. Patients and physicians need to be aware of the elevated risk as they make treatment decisions."

The principal systemic therapy for prostate cancer involves blocking testosterone production. This is done either by removal of the testes (bilateral orchiectomy), or more commonly, by regular injections of a gonadotropin-releasing hormone (GnRH) agonist drug. GnRH agonists are the main therapy for metastatic prostate cancer and may also improve survival for some men with locally advanced cancers.

However, little is known about the efficacy of GnRH agonists in treating men with less-advanced local or regional prostate cancer, many of whom receive this therapy. Earlier studies have found GnRH agonists to be associated with obesity and insulin resistance, a precursor to diabetes.

"Our study found that men with local or regional prostate cancer receiving a GnRH agonist had a 44 percent higher risk of developing diabetes and a 16 percent higher risk of developing coronary heart disease than men who were not receiving hormone therapy," says Keating, who is also a physician at Brigham and Women's Hospital.

"Doctors should think twice about prescribing GnRH agonists in situations for which studies have not demonstrated improved survival until we better understand the risks of treatment," says co-author Matthew Smith, MD, PhD, associate professor of medicine at HMS and a medical oncologist at Massachusetts General Hospital. "For men who do require this treatment, physicians may want to talk with their patients about strategies, such as exercise and weight loss, which may help to lower risk of diabetes and heart disease."

This work was supported by the Prostate Cancer Specialized Program of Research Excellence (SPORE) of the National Cancer Institute, one of the National Institutes of Health.

all Matthew R. Smith stories

Microchip-based device can detect rare tumor cells in bloodstream

Prostate treatment has risks

Prostate cancer treatment increases risk of diabetes, heart disease